Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Cathie Wood Rotates Into Tesla and Snowflake
19.06.2026 12:08
ARK shifts exposure toward growth and cloud
Novo Bets Bigger on Obesity Research
19.06.2026 12:08
The foundation behind Novo Nordisk is funding a new effort to turn scientific discoveries into treatments.
Eli Lilly & Co (NYSE:LLY): A Dividend Growth Gem with Strong Fundamentals
19.06.2026 11:10
Eli Lilly (LLY) offers a low 0.61% yield but stands out with 15.17% annual dividend growth and a sustainable 22% payout ratio. Strong profitability and solid financial health make it a top pick for dividend growth investors.
Charles River collaborates with Lilly TuneLab platform
19.06.2026 10:07
By incorporating nonclinical testing services, the partnership seeks to standardise testing protocols across organisations.
ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain
19.06.2026 09:13
RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their widespread use in cancer care.
Under Dave Ricks, Lilly Is Minting Money on GLP-1 Drugs and Spending It Wisely
19.06.2026 05:00
Ricks has led a $50 billion manufacturing Marshall Plan in pharma to safeguard Lilly’s lead in obesity and diabetes treatments.
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
18.06.2026 14:11
PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.
Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?
18.06.2026 14:01
Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
18.06.2026 13:51
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs
18.06.2026 13:32
SAN FRANCISCO, June 18, 2026--Chai Discovery, the AI company engineering models to discover new molecules, today announced that certain Chai Discovery frontier AI model capabilities will be made available to companies participating in the Lilly TuneLab platform.
Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
18.06.2026 12:00
WILMINGTON, Mass., June 18, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).
What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals Emerge
18.06.2026 08:08
Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 3 years. On June 15, Eli Lilly and Company (NYSE:LLY) shared new data from the Phase 1 AJX-101 study. The study showed that an investigational type II JAK2 inhibitor delivered an “encouraging” safety profile, demonstrating clinical activity in […]
Axcelead DDP Joins Lilly TuneLab to Advance AI Drug Discovery
18.06.2026 05:00
FUJISAWA, Japan, June 18, 2026--Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) is pleased to announce that it has entered a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).
Novo Nordisk: A Fallen Leader Trading At Fair Value, Not A Bargain
17.06.2026 03:39
Novo Nordisk has lost GLP-1 leadership against Eli Lilly. Click here to read more about NVO stock and why it is a Hold.
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
15.06.2026 14:40
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?
15.06.2026 14:04
PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
15.06.2026 12:45
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in pos
Novo Nordisk: The Danish Empire Strikes Back
15.06.2026 08:34
Novo Nordisk leverages Wegovy pill growth and long-term patent protection to overcome a weak 2026 guidance. Read the analysis of NVO stock here.
India's Electronics Mart eyes new markets as tech hubs fear job losses
15.06.2026 05:31
Hyderabad-based Electronics Mart India is looking to diversify away from the technology hub as concerns grow that potential AI-triggered job losses could hurt consumer spending, a top executive said. The retailer gets about 60% of its revenue from Hyderabad, which hosts offices of global companies such as JPMorgan Chase and Eli Lilly, and Indian IT majors Wipro and Infosys. Around a fifth of its stores in Hyderabad are located in neighbourhoods where the majority of the residents are software employees.
Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside
15.06.2026 03:10
Eli Lilly (NYSE:LLY) reported Phase 1 data for AJ1-11095, a first-in-class type II JAK2 inhibitor, in myelofibrosis patients. The AJX-101 study focused on individuals whose disease continued after prior type I JAK2 inhibitor treatment. Early results showed encouraging safety findings and clinical activity in this difficult to treat group. Eli Lilly is widely associated with its obesity drug portfolio, but the AJ1-11095 update highlights a broader pipeline that includes hematology and...